Bluebird chooses partner for manufacture of its first approved product

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Master1305)
(Image: Getty/Master1305)

Related tags: bluebird bio, apceth Biopharma, Zyntelgo, Gene therapy

Apceth announces that it will be responsible for the commercial manufacture of Zyntelgo, after its approval last week.

The European Commission’s conditional approval for Zyntelgo (autologous CD34+ cells encoding βA-T87Q-globin gene) saw bluebird bio receive its first approval​.

Shortly after, apceth Biopharma noted that it would continue its partnership with bluebird to be the commercial manufacturer of the product in Europe.

Christine Guenther, CEO of apceth Biopharma, said, “Being one of the very few companies worldwide to manufacture a cell-based gene therapy for commercial use marks a milestone for our company.”

The partnership between the two companies has been ongoing since 2016 and also sees apceth manufacture drug product for bluebird’s Lenti-D, an investigational treatment for cerebral adrenoleukodystrophy.

With several products nearing approval decisions​, bluebird is stepping up its own manufacturing capabilities.

Previously, bluebird added a 125,000-square-foot manufacturing facility​ to its network in North Carolina, US, in 2017. While earlier this year, the company opened its first manufacturing facility​ for the production of lentiviral vectors.

At the time of the latter deal, bluebird emphasised that the purchase was a means to ‘complement’ its existing, external manufacturing partners.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more